Insulin delivery technology and eating behaviours in people with type 1 diabetes
Official title: The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes
Run by McGill University · NCT07348432 · Data updated 2026-11-12
This project will test whether automated insulin delivery systems change eating behaviours and make carbohydrate counting easier for people aged 12 and older who have type 1 diabetes in Canada.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 12 Years and up |
| Sex | All |
| Enrollment | 106 (estimated) |
| Sponsor | McGill University Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | July 29, 2024 |
| Main results expected | October 31, 2026 |
| Study ends | April 30, 2027 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT07348432 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 12 or older living in Canada with type 1 diabetes for more than one year who use at least two daily insulin injections or an insulin pump and have used their current insulin delivery system for three months or more.
✕Probably not a fit
People who are pregnant or breastfeeding, do not speak English or French, lack a smartphone, or live outside Canada are not eligible and therefore will not benefit from participation in this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a cross-sectional observational study comparing people with type 1 diabetes who use automated insulin delivery (AID) systems to those using non-automated delivery. The study measures disordered eating behaviours, carbohydrate counting accuracy, and glycemic stability, and looks for differences by gender and by age group including youth (12–17 years). Participants provide data via smartphone apps and existing glucose/insulin device records, and carbohydrate-counting inaccuracy thresholds for maintaining glucose control will be estimated for each delivery type. The goal is to understand whether AID use is linked to lower food-management burden or different patterns of disordered eating.
Why it matters
Potential benefit: If successful, the findings could help tailor diabetes technology choices and education to reduce eating-related burden and lower risk of disordered eating while maintaining glucose control.
How similar studies have gone: Previous studies show AID systems improve glycemic control and quality of life, but their specific effects on eating behaviours and disordered eating are largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 12 years of age or older * Living in Canada * Living with type 1 diabetes for more than 1 year * Using at least 2 insulin injections per day or using an insulin pump * Using current insulin delivery system for 3 months or more Exclusion Criteria: * Are pregnant or currently are breastfeeding * Don't speak French or English * Does not have a smart phone (to download applications)
Where it's running
-
McGill University
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Anne-Sophie Brazeau, PhD — McGill University
- Study coordinator: Courtney South, MSc
- Email: courtney.south@mail.mcgill.ca
- Phone: 705-527-4843
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using the 'Support' online training and peer program for adults with type 1 diabetes
This project will test whether adults with type 1 diabetes who get access to the online 'Support' training and peer platform through their diabetes clinic manage their diabetes better than those who use the platform on their own.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
-
Telehealth Music Therapy for adults with autoimmune endocrine disease and depression
This study tests whether eight weeks of telehealth music therapy can improve quality of life and mood symptoms in adults with autoimmune endocrine diseases and depression.
-
Healthier Lifestyles for Teens with Type 1 Diabetes
We will try a tailored lifestyle program (T1DAL) to help teens with type 1 diabetes who are overweight or at risk of obesity improve their health and reduce risk of disordered eating.
-
Investigating the safety and effectiveness of porcine pancreatic cells in patients with Type 1 diabetes
This study is testing if using pig pancreas cells can help adults with tough-to-manage Type 1 diabetes feel better and avoid dangerous low blood sugar episodes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.